# Nuclide record b-rlt-trial-capacity (bottleneck). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/bottlenecks/b-rlt-trial-capacity/>
  a schema:Thing ;
  nuclide:kind "bottleneck" ;
  schema:identifier "b-rlt-trial-capacity" ;
  schema:name "Clinical trial capacity for radioligand therapy"@en ;
  schema:description "There are so many new radioactive cancer drugs now being tested that the trials themselves compete with each other, and with approved treatments, for the same scarce radioactive material, the same specially licensed hospital rooms, and the same trained staff. Sometimes a trial has to pause enrolling new patients simply because the isotope has run out."@en ;
  schema:url <https://nuclide.cc/bottlenecks/b-rlt-trial-capacity/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.fiercepharma.com/pharma/bms-and-rayzebio-halt-radiotherapy-trial-enrollment-after-isotope-runs-scarce>, <https://myscrs.org/preparing-clinical-sites-radiopharmaceutical-trials/>, <https://intuitionlabs.ai/articles/radioligand-therapy-manufacturing-capacity> ;
  nuclide:tag "clinical trials", "capacity", "isotope supply" ;
  nuclide:related <https://nuclide.cc/bottlenecks/b-ac225-supply/>, <https://nuclide.cc/bottlenecks/b-hot-lab-capacity/>, <https://nuclide.cc/bottlenecks/b-site-readiness-referral/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:technologies <https://nuclide.cc/technologies/therapy-isotope-supply-chain/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/technologies/lu177-radioligand-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:companies <https://nuclide.cc/companies/rayzebio/>, <https://nuclide.cc/companies/bms/>, <https://nuclide.cc/companies/novartis/> ;
  nuclide:trials <https://nuclide.cc/trials/action-1/> .